Join to View Full Profile
5255 Loughboro Road NorthwestWashington, DC 20016
Phone+1 202-660-6500
Fax+1 202-660-6501
Dr. Pishvaian is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
MedStar Health Georgetown UniversityFellowship, Hematology and Medical Oncology, 2004 - 2007- MedStar Health Georgetown University/Georgetown HospitalResidency, Internal Medicine, 2001 - 2004
Georgetown University School of MedicineClass of 2001
Certifications & Licensure
DC State Medical License 2004 - 2027
MD State Medical License 2010 - 2025
TX State Medical License 2019 - 2020
VA State Medical License 2001 - 2010
American Board of Internal Medicine Medical Oncology
Clinical Trials
- Study of Ulixertinib for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations Start of enrollment: 2021 Jan 07
Roles: Contact, Principal Investigator
- A Study of TAK-981 Given With Pembrolizumab in Participants With Select Advanced or Metastatic Solid Tumors Start of enrollment: 2020 Aug 17
Roles: Principal Investigator
- Study of EO-3021 in Adult Patients With Solid Tumors Likely to Express CLDN18.2 Start of enrollment: 2023 Aug 10
Roles: Contact
Publications & Presentations
PubMed
- Targeting BARD1 suppresses a Myc-dependent transcriptional program and tumor growth in pancreatic ductal adenocarcinoma.Sohum Patel, Eleanor Jenkins, Rutuj P Kusurkar, Sherry Lee, Wei Jiang
Neoplasia. 2025-05-01 - Distinct Molecular and Clinical Features of Specific Variants of KRAS Codon 12 in Pancreatic Adenocarcinoma.Bach Ardalan, Aaron Ciner, Yasmine Baca, Andrew Hinton, Sourat Darabi
Clinical Cancer Research. 2025-03-17 - Clinical outcomes and molecular characteristics of lung-only and liver-only metastatic pancreatic cancer: results from a real-world evidence database.Abrahm Levi, Edik Blais, John Davelaar, Matthew I Ebia, Angela Minasyan
The Oncologist. 2025-03-10
Press Mentions
Johns Hopkins Medicine Initiates Patient Enrollment for RenovoRx’s Ongoing Phase III TIGeR-PaC Clinical TrialApril 29th, 2025
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
